Sex steroid hormones and reproductive disorders: Impact on women's health

Reproductive Sciences

Volumn 18, Issue 8, 2011, Pages 702-712

  Fauser, Bart C J M ^a   Laven, Joop S E ^b   Tarlatzis, Basil C ^c   Moley, Kelle H ^d   Critchley, Hilary O D ^e   Taylor, Robert N ^f   Berga, Sarah L ^f   Mermelstein, Paul G ^g   Devroey, Paul ^h   Gianaroli, Luca ⁱ   D'Hooghe, Thomas ^j   Vercellini, Paolo ^k   Hummelshoj, Lone ^l   Rubin, Susan ^m   Goverde, Angelique J ^a   Leo, Vincenzo De ⁿ   Petraglia, Felice ⁿ  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d WASHINGTON UNIVERSITY   (United States)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

ⁱ SISMeR   (Italy)

^j University Fertility Center   (Belgium)

^k UNIVERSITY OF MILAN   (Italy)

^l World Endometriosis Research Foundation   (United Kingdom)

^m NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

ⁿ UNIVERSITY OF SIENA   (Italy)

more..

Author keywords

endometrial diseases; endometriosis; polycystic ovary syndrome; post menopausal syndrome; primary ovarian insufficiency; sex hormones

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANDROGEN RECEPTOR; CYCLIC AMP; ESTROGEN RECEPTOR; FOLLITROPIN; INTERLEUKIN 8; ORAL CONTRACEPTIVE AGENT; PROGESTERONE RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRICARBOXYLIC ACID;

ACNE; ALZHEIMER DISEASE; ATHEROSCLEROSIS; BONE DENSITY; DEMENTIA; ENDOMETRIOSIS; ENERGY EXPENDITURE; ESTRADIOL BLOOD LEVEL; FERTILITY; GENE MUTATION; HIRSUTISM; HORMONE SUBSTITUTION; HUMAN; LUTEINIZING HORMONE RELEASE; MATERNAL HYPERTENSION; MENOPAUSAL SYNDROME; MENSTRUATION DISORDER; OBESITY; OOCYTE DONATION; OSTEOPOROSIS; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REVIEW; SEXUALITY;

ENDOMETRIOSIS; FEMALE; GONADAL STEROID HORMONES; HUMANS; POLYCYSTIC OVARY SYNDROME; POSTMENOPAUSE; PRIMARY OVARIAN INSUFFICIENCY;

EID: 79961061080     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719111405068     Document Type: Review

References (80)

1. Foryst-Ludwig A, Kintscher U. Metabolic impact of estrogen signalling through ERalpha and ERbeta. J Steroid Biochem Mol Biol. 2010 ; 122 (1-3). 74-81
2. Scarpin KM, Graham JD, Mote PA, Clarke CL. Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression. Nucl Recept Signal. 2009 ; 7: e009
3. Frye CA. Steroids, reproductive endocrine function, and cognition. A review. Minerva Ginecol. 2009 ; 61 (6). 563-585
4. De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet. 2010 ; 376 (9744). 911-921
5. Nelson L. Primarian ovarian insufficiency. N Engl J Med. 2009 ; 360 (5). 606-614
6. Current evaluation ofamenorrhea. Fertil Steril. 2004 ; 82 (suppl 1). S33 - S39
7. Pines A, Sturdee DW, Birkhäuser MH, Schneider HP, Gambacciani M, Panay N. IMS updated recommendations on postmenopausal hormone therapy. Climacteric. 2007 ; 10 (3). 181-194 (Pubitemid 46752441)
8. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogenreplacementtherapy with venous thromboembolism risk. Lancet. 2003 ; 362 (9382). 428-432 (Pubitemid 36999704)
9. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism amongpostmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007 ; 115 (7). 840-845 (Pubitemid 46294724)
10. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005 ; 352 (12). 1223-1236
11. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997 ; 18 (6). 774-800 (Pubitemid 28009567)
12. Solomon CG, Hu FB, Dunaif A, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab. 2002 ; 87 (5). 2013-2017 (Pubitemid 34521483)
13. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999 ; 84 (1). 165-169 (Pubitemid 29036695)
14. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004 ; 19 (1). 41-47
15. Azziz R, Carmina E, Dewailly D, et al. Task force on the phenotype of the polycystic ovary syndrome of the androgen excess and PCOS Society. The androgen excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009 ; 91 (2). 456-488
16. Eisner JR, Dumesic DA, Kemnitz JW, Abbott DH. Timing of prenatal androgen excess determines differential impairment in insulin secretion and action in adult female rhesus monkeys. J Clin Endocrinol Metab. 2000 ; 85 (3). 1206-1210 (Pubitemid 32269373)
17. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome-a hypothesis. J Endocrinol. 2002 ; 174 (1). 1-5 (Pubitemid 34830927)
18. Legro RS, Driscoll D, Strauss JF, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A. 1998 ; 95 (25). 14956-14960 (Pubitemid 29003738)
19. Franks S, McCarthy M. Genetics of ovarian disorders: polycystic ovary syndrome. Rev Endocr Metab Disord. 2004 ; 5 (1). 69-76 (Pubitemid 38374699)
20. Legro RS, Bentley-Lewis R, Driscoll D, Wang SC, Dunaif A. Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity. J Clin Endocrinol Metab. 2002 ; 87 (5). 2128-2133 (Pubitemid 34521498)
21. Laven JS, Mulders AG, Suryandari DA, et al. Follicle-stimulating hormone receptor polymorphisms in women with normogonadotropic anovulatory infertility. Fertil Steril. 2003 ; 80 (4). 986-992 (Pubitemid 37230037)
22. Conway GS, Ruokonen A, Martikainen H, et al. Analysis of multiple data sets reveals no association between the insulin gene variable number tandem repeat element and polycystic ovary syndrome or related traits. J Clin Endocrinol Metab. 2005 ; 90 (5). 2988-2993 (Pubitemid 40686354)
23. Stolk L, Zhai G, van Meurs JB, et al. Loci at chromosomes 13, 19 and 20 influence age at natural menopause. Nat Genet. 2009 ; 41 (6). 645-647
24. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril. 2008 ; 89 (3). 505-522
25. Zhang HY, Zhu FF, Xiong J, Shi XB, Fu SX. Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population. BJOG. 2009 ; 116 (12). 1633-1639
26. De Leo V, Musacchio MC, Palermo V, Di Sabatino A, Morgante G, Petraglia F. Polycystic ovary syndrome and metabolic comorbidities: therapeutic options. Drugs Today. 2009 ; 45 (10). 763-775
27. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010 ; 8: 41
28. Azziz R, Carmina E, Dewailly D, et al. The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report. Task force on the phenotype of the polycystic ovary syndrome of the androgen excess and PCOS society. Fertil Steril. 2009 ; 91 (2). 456-488
29. Wang Q, Ratchford AM, Chi MM, et al. Maternal diabetes causes mitochondrial dysfunction and meiotic defects in murine oocytes. Mol Endocrinol. 2009 ; 23 (10). 1603-1612
30. Giudice LC. Endometrium in PCOS: implantation and predisposition to endocrine CA. Best Pract Res Clin Endocrinol Metab. 2006 ; 20 (2). 235-244 (Pubitemid 43842928)
31. Homburg R. Pregnancy complications in PCOS. Best Pract Res Clin Endocrinol Metab. 2006 ; 20 (2). 281-292 (Pubitemid 43842931)
32. Ratchford AM, Esguerra CR, Moley KH. Decreased oocyte-granulosa cell gap junction communication and connexin expression in a type 1 diabetic mouse model. Mol Endocrinol. 2008 ; 22 (12). 2643-2654
33. Kim K, Kim CH, Moley KH, Cheon YP. Disordered meiotic regulation of oocytes by duration of diabetes mellitus in BBdp rat. Reprod Sci. 2007 ; 14 (5). 467-474 (Pubitemid 351168801)
34. Siassakos D, Wardle P. Polycystic ovary syndrome and pregnancy outcome: red herring or red flag?. BJOG. 2007 ; 114 (8). 922-932 (Pubitemid 47052762)
35. Altieri P, Gambineri A, Prontera O, Cionci G, Franchina M, Pasquali R. Maternal polycystic ovary syndrome may be associated with adverse pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol. 2010 ; 149 (1). 31-36
36. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update. 2006 ; 12 (6). 673-683 (Pubitemid 44605508)
37. Hirschberg AL. Polycystic ovary syndrome, obesity and reproductive implications. Womens Health (Lond Engl). 2009 ; 5 (5). 529-540
38. Denison FC, Roberts KA, Barr SM, Norman JE. Obesity, pregnancy, inflammation, and vascular function. Reproduction. 2010 ; 140 (3). 373-385
39. Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update. 2009 ; 15 (4). 477-488
40. Meyer C, McGrath BP, Cameron J, Kotsopoulos D, Teede HJ. Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. J Clin Endocrinol Metab. 2005 ; 90 (8). 4630-4635 (Pubitemid 41159353)
41. De Leo V, Musacchio M. C, Palermo V, Di Sabatino A, Morgante G., Petraglia F. Polycistic ovary syndrome and metabolic comorbidities: therapeutic options. Drugs Today (Barc) Rev. 2009 ; 45 (10). 763-75
42. Maybin JA, Critchley HO. Repair and regeneration of the human endometrium. Expert Rev Obstetr Gynaecol. 2009 ; 4 (2). 283-298
43. King AE, Critchley HO. Oestrogen and progesterone regulation of inflammatory processes in the human endometrium. J Steroid Biochem Mol Biol. 2010 ; 120 (2-3). 116-126
44. Heavy menstrual bleeding. Clinical Guideline. 2007 ; 44 (6). 25-26
45. Gaide Chevronnary HP, Galant C, Lemoine P, Courtoy PJ, Marbaix E, Henriet P. Spatiotemporal coupling of focal extracellular matrix degradation and reconstruction in the menstrual human endometrium. Endocrinology. 2009 ; 150 (11). 5094-5105
46. Fan X, Krieg S, Kuo CJ, et al. VEGF blockade inhibits angiogenesis and re-epithelialization of endometrium. FASEB J. 2008 ; 22 (12). 3571-3580
47. Hannan NJ, Jones RL, Critchley HO, et al. Coexpression of fractalkine and its receptor in normal human endometrium and in endometrium from users of progestin-only contraception supports a role for fractalkine in leukocyte recruitment and endometrial remodeling. J. Clin Endocrinol Metab. 2004 ; 89 (12). 6119-6129 (Pubitemid 39628424)
48. Small GR, Hadoke PW, Sharif I, et al. Preventing local regeneration of glucocorticoids by 11β-hydroxysteroid dehydrogenase type 1 enhances angiogenesis. Proc Natl Acad Sci USA. 2005 ; 102 (34). 12165-12170 (Pubitemid 41291146)
49. Rae M, Mohamad A, Price D, et al. Cortisol inactivation by 11βHSD2 may enhance endometrial angiogenesis via reduced thrombospondin-1 in heavy menstruation. J Clin Endocrinol Metab. 2009 ; 94 (4). 1443-1450
50. Farquar C, Brown J. Oral contraceptive pill for heavy menstrual bleeding. Cochrane Database Syst Rev. 2009 ; 4: CD000154
51. Adamson GD, Kennedy SH, Hummelshoj L. Creating solutions in endometriosis: global collaboration through the World Endometriosis Research Foundation. J Endometriosis. 2010 ; 2 (2). 3-6
52. Simoens S, Hummelshoj L, D'Hooghe T. Endometriosis: cost estimates and methodological perspective. Hum Reprod Update. 2007 ; 13 (4). 395-404 (Pubitemid 47062831)
53. Ryan IP, Schriock ED, Taylor RN. Isolation, characterization, and comparison of human endometrial and endometriosis cells in vitro. J Clin Endocrinol Metab. 1994 ; 78 (3). 642-649 (Pubitemid 24083305)
54. Luisi S, Galleri L, Marini F, Ambrosini G, Brandi ML, Petraglia F. Estrogen receptor gene polymorphisms are associated with recurrence of endometriosis. Fertil Steril. 2006 ; 85 (3). 764-766 (Pubitemid 43261583)
55. Braun DP, Ding J, Shaheen F, Willey JC, Rana N, Dmowski WP. Quantitative expression of apoptosis-regulating genes in endometrium from women with and without endometriosis. Fertil Steril. 2007 ; 87 (2). 263-268 (Pubitemid 46188440)
56. Brandenberger AW, Lebovic DI, Tee MK, et al. Oestrogen receptor (ER)-alpha and ER-beta isoforms in normal endometrial and endometriosis-derived stromal cells. Mol Hum Reprod. 1999 ; 5 (7). 651-655 (Pubitemid 29317755)
57. Xue Q, Lin Z, Cheng YH, et al. Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis. Biol Reprod. 2007 ; 77 (4). 681-687 (Pubitemid 47494383)
58. Bulun SE. Endometriosis. N Eng J Med. 2009 ; 360 (3). 268-279
59. Wieser F, Yu J, Park J, et al. A botanical extract from channel flow inhibits cell proliferation, induces apoptosis, and suppresses CCL5 in human endometriotic stromal cells. Biol Reprod. 2009 ; 81 (2). 371-377
60. Lebovic DI, Baldocchi RA, Mueller MD, Taylor RN. Altered expression of a cell-cycle suppressor gene, Tob-1, in endometriotic cells by cDNA array analyses. Fertil Steril. 2002 ; 78 (4). 849-854
61. Attia GR, Zeitoun K, Edwards D, Johns A, Carr BR, Bulun SE. Progesterone receptor isoform A but not B is expressed in endometriosis. J Clin Endocrinol Metab. 2000 ; 85 (8). 2897-2902 (Pubitemid 32269170)
62. Taylor RN, Lundeen SG, Giudice LC. Emerging role of genomics in endometriosis research. Fertil Steril. 2002 ; 78 (4). 694-698
63. Galleri L, Luisi S, Rotondi M, et al. Low serum and peritoneal fluid concentration of interferon-gamma-induced protein-10 (CXCL10) in women with endometriosis. Fertil Steril. 2009 ; 91 (2). 331-334
64. Wieser F, Vigne JL, Ryan I, Hornung D, Djalali S, Taylor RN. Sulindac suppresses nuclear factor-kappaB activation and RANTES gene and protein expression in endometrial stromal cells from women with endometriosis. J Clin Endocrinol Metab. 2005 ; 90 (12). 6441-6447 (Pubitemid 41759297)
65. Mermelstein PG, Micevych PE. Nervous system physiology regulated by membrane estrogen receptors. Rev Neurosci. 2008 ; 19 (6). 413-424
66. Boulware MI, Weick JP, Becklund BR, Kuo SP, Groth RD, Mermelstein PG. Estradiol activates group I and II metabotropic glutamate receptor signalling, leading to opposing influences on cAMP response element-binding protein. J Neurosci. 2005 ; 25 (20). 5066-5078 (Pubitemid 40712851)
67. Boulware MI, Kordasiewicz H, Mermelstein PG. Caveolin proteins are essential for distinct effects of membrane estrogen receptors in neuons. J Neurosci. 2007 ; 27 (37). 9941-9950 (Pubitemid 47403995)
68. Foradori CD, Weiser MJ, Handa RJ. Non-genomic actions of androgens. Front Neuroendocrinol. 2008 ; 29 (2). 169-181
69. Michels G, Hoppe UC. Rapid actions of androgens. Front Neuroendocrinol. 2008 ; 29 (2). 182-198
70. Marino M, Ascenzi P, Acconcia F. S-palmitoylation modulates estrogen receptor alpha localization and functions. Steroids. 2006 ; 71 (4). 298-303
71. Marino M, Ascenzi P. Steroid hormone rapid signaling: the pivotal role of S-palmitoylation. IUBMB Life. 2006 ; 58 (12). 716-719 (Pubitemid 46900132)
72. Levin ER. Plasma membrane estrogen receptors. Trends Endocrinol Metab. 2009 ; 20 (10). 477-482
73. Hatzoglou A, Kampa M, Kogia C, et al. Membrane androgen receptor activation induces apoptotic regression of human prostate cancer cells in vitro and in vivo. J Clin Endocrinol. 2005 ; 90 (2). 893-903 (Pubitemid 40279214)
74. Pazol K, Wilson ME, Wallen K. Medroxyprogesterone acetate antagonizes the effects of estrogen treatment on social and sexual behavior in female macaques. J Clin Endocrinol Metab. 2004 ; 89 (6). 2998-3006 (Pubitemid 38766400)
75. Bender CM, Sereika SM, Berga SL, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology. 2006 ; 15 (5). 422-430 (Pubitemid 43826855)
76. Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ. 2010 ; 340: c2519
77. Berga SL, Loucks TL. Does postmenopausal estrogen use confer neuroprotection? Seminars in reproductive medicine, sex hormones and brain. Carr and Simpson (guest ed). Semin Reprod Med. 2009 ; 27 (5). 260-274
78. Moses-Kolko EL, Berga SL, Greer PJ, Smith G, Meltzer CC, Drevets WC. Widespread increases of cortical serotonin (5HT2A) receptor availability following hormone replacement therapy in euthymic postmenopausal women. Fertil Steril. 2003 ; 80 (3). 554-559 (Pubitemid 37102865)
79. North American Menopause Society Position statement: estrogen and progestogen use in peri- and postmenopausal. Women Menopause. 2007 ; 14 (5). 168-182
80. Powell BL, Haddad L, Bennett A, et al. Analysis of multiple data sets reveals no association between the insulin gene variable number tandem repeat element and polycystic ovary syndrome or related traits. J Clin Endocrinol Metab. 2005 ; 90 (5). 2988-2993 (Pubitemid 40686354)